1. Home
  2. ADPT vs UMH Comparison

ADPT vs UMH Comparison

Compare ADPT & UMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • UMH
  • Stock Information
  • Founded
  • ADPT 2009
  • UMH 1968
  • Country
  • ADPT United States
  • UMH United States
  • Employees
  • ADPT N/A
  • UMH N/A
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • UMH Real Estate Investment Trusts
  • Sector
  • ADPT Health Care
  • UMH Real Estate
  • Exchange
  • ADPT Nasdaq
  • UMH Nasdaq
  • Market Cap
  • ADPT 1.8B
  • UMH 1.4B
  • IPO Year
  • ADPT 2019
  • UMH N/A
  • Fundamental
  • Price
  • ADPT $10.75
  • UMH $16.81
  • Analyst Decision
  • ADPT Strong Buy
  • UMH Strong Buy
  • Analyst Count
  • ADPT 7
  • UMH 4
  • Target Price
  • ADPT $10.57
  • UMH $21.00
  • AVG Volume (30 Days)
  • ADPT 2.1M
  • UMH 471.2K
  • Earning Date
  • ADPT 08-05-2025
  • UMH 08-06-2025
  • Dividend Yield
  • ADPT N/A
  • UMH 5.35%
  • EPS Growth
  • ADPT N/A
  • UMH N/A
  • EPS
  • ADPT N/A
  • UMH 0.10
  • Revenue
  • ADPT $189,527,000.00
  • UMH $243,777,000.00
  • Revenue This Year
  • ADPT $24.39
  • UMH $6.95
  • Revenue Next Year
  • ADPT $20.44
  • UMH $7.07
  • P/E Ratio
  • ADPT N/A
  • UMH $161.85
  • Revenue Growth
  • ADPT 8.61
  • UMH 8.17
  • 52 Week Low
  • ADPT $3.85
  • UMH $15.74
  • 52 Week High
  • ADPT $12.43
  • UMH $20.64
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 48.31
  • UMH 45.59
  • Support Level
  • ADPT $10.22
  • UMH $16.77
  • Resistance Level
  • ADPT $11.18
  • UMH $17.20
  • Average True Range (ATR)
  • ADPT 0.51
  • UMH 0.28
  • MACD
  • ADPT -0.15
  • UMH -0.01
  • Stochastic Oscillator
  • ADPT 24.82
  • UMH 26.67

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About UMH UMH Properties Inc.

UMH Properties Inc together with its subsidiaries is a real estate investment trust. It is engaged in the business of ownership and operation of manufactured home communities - leasing manufactured homesites to residents . The Company also leases manufactured homes to residents and, through its wholly-owned taxable REIT subsidiary, UMH Sales and Finance, Inc. sells and finances the sale of manufactured homes to residents and prospective residents of its communities and for placement on customers' privately-owned land. The company also owns the land, utility connections, streets, lighting, driveways, common area amenities, and other capital improvements. It earns income from lease agreements for their sites and homes, where the company is the lessor.

Share on Social Networks: